1000010101O
2021-12-03
[Smile]
Advent, Aurora withdraws $8 bln bid for Swedish drugmaker Sobi
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":601635523,"tweetId":"601635523","gmtCreate":1638521185939,"gmtModify":1638521185939,"author":{"id":3581326346667529,"idStr":"3581326346667529","authorId":3581326346667529,"authorIdStr":"3581326346667529","name":"1000010101O","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":9,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p><span>[Smile] </span><br></p></body></html>","htmlText":"<html><head></head><body><p><span>[Smile] </span><br></p></body></html>","text":"[Smile]","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/601635523","repostId":2188900542,"repostType":4,"repost":{"id":"2188900542","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1638518208,"share":"https://www.laohu8.com/m/news/2188900542?lang=&edition=full","pubTime":"2021-12-03 15:56","market":"us","language":"en","title":"Advent, Aurora withdraws $8 bln bid for Swedish drugmaker Sobi","url":"https://stock-news.laohu8.com/highlight/detail?id=2188900542","media":"Reuters","summary":"STOCKHOLM, Dec 3 (Reuters) - U.S. private equity firm Advent International and Singapore's sovereign","content":"<p>STOCKHOLM, Dec 3 (Reuters) - U.S. private equity firm Advent International and Singapore's sovereign wealth fund on Friday said they are withdrawing their bid for Swedish drugmaker Orphan Biovitrum (Sobi), citing a low acceptance level.</p>\n<p>Sobi in September agreed to an $8 billion takeover by Advent and Aurora, an investment vehicle of Singapore's GIC Pte Ltd, through Agnafit Bidco.</p>\n<p>\"Since the acceptance level condition has not been fulfilled, Agnafit Bidco hereby withdraws the offer,\" Agnafit Bidco said in a statement.</p>\n<p>Having soared 36% this year, Sobi shares closed at 226.60 crowns ($24.9) on Thursday, below the 235 crowns per share offer, which represented a premium of 34.5% to its Aug. 25 closing price.</p>\n<p>Sweden's Investor AB, which owns 35% of the shares in the rare disease drugmaker, said in a statement that its focus would now be to \"continue to create long-term value for Sobi's shareholders\".</p>\n<p>Agnafit said shares corresponding to around 87.3% of outstanding shares in Sobi, which sells drugs within haemophilia, autoimmune diseases, metabolic diseases and cancer supportive care, had been tendered, below its condition of more than 90%.</p>\n<p>Sobi's best-selling drug, established haemophilia A treatment Elocta, with 4.6 billion crowns in 2020 revenues, is facing competition from Roche's Hemlibra.</p>\n<p>($1 = 9.1125 Swedish crowns)</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Advent, Aurora withdraws $8 bln bid for Swedish drugmaker Sobi</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdvent, Aurora withdraws $8 bln bid for Swedish drugmaker Sobi\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-03 15:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>STOCKHOLM, Dec 3 (Reuters) - U.S. private equity firm Advent International and Singapore's sovereign wealth fund on Friday said they are withdrawing their bid for Swedish drugmaker Orphan Biovitrum (Sobi), citing a low acceptance level.</p>\n<p>Sobi in September agreed to an $8 billion takeover by Advent and Aurora, an investment vehicle of Singapore's GIC Pte Ltd, through Agnafit Bidco.</p>\n<p>\"Since the acceptance level condition has not been fulfilled, Agnafit Bidco hereby withdraws the offer,\" Agnafit Bidco said in a statement.</p>\n<p>Having soared 36% this year, Sobi shares closed at 226.60 crowns ($24.9) on Thursday, below the 235 crowns per share offer, which represented a premium of 34.5% to its Aug. 25 closing price.</p>\n<p>Sweden's Investor AB, which owns 35% of the shares in the rare disease drugmaker, said in a statement that its focus would now be to \"continue to create long-term value for Sobi's shareholders\".</p>\n<p>Agnafit said shares corresponding to around 87.3% of outstanding shares in Sobi, which sells drugs within haemophilia, autoimmune diseases, metabolic diseases and cancer supportive care, had been tendered, below its condition of more than 90%.</p>\n<p>Sobi's best-selling drug, established haemophilia A treatment Elocta, with 4.6 billion crowns in 2020 revenues, is facing competition from Roche's Hemlibra.</p>\n<p>($1 = 9.1125 Swedish crowns)</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIOVF":"Swedish Orphan Biovitrum AB"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2188900542","content_text":"STOCKHOLM, Dec 3 (Reuters) - U.S. private equity firm Advent International and Singapore's sovereign wealth fund on Friday said they are withdrawing their bid for Swedish drugmaker Orphan Biovitrum (Sobi), citing a low acceptance level.\nSobi in September agreed to an $8 billion takeover by Advent and Aurora, an investment vehicle of Singapore's GIC Pte Ltd, through Agnafit Bidco.\n\"Since the acceptance level condition has not been fulfilled, Agnafit Bidco hereby withdraws the offer,\" Agnafit Bidco said in a statement.\nHaving soared 36% this year, Sobi shares closed at 226.60 crowns ($24.9) on Thursday, below the 235 crowns per share offer, which represented a premium of 34.5% to its Aug. 25 closing price.\nSweden's Investor AB, which owns 35% of the shares in the rare disease drugmaker, said in a statement that its focus would now be to \"continue to create long-term value for Sobi's shareholders\".\nAgnafit said shares corresponding to around 87.3% of outstanding shares in Sobi, which sells drugs within haemophilia, autoimmune diseases, metabolic diseases and cancer supportive care, had been tendered, below its condition of more than 90%.\nSobi's best-selling drug, established haemophilia A treatment Elocta, with 4.6 billion crowns in 2020 revenues, is facing competition from Roche's Hemlibra.\n($1 = 9.1125 Swedish crowns)","news_type":1},"isVote":1,"tweetType":1,"viewCount":238,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":7,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/601635523"}
精彩评论